Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts

References

• Kochanek KD, Xu J, Murphy SL, et al. Deaths: final data for 2009. National Vital Statistics Reports 2011;60:1-167
   Google Scholar
• Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123:933-44
   PubMed Web of Science ®Google Scholar
• Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary. JACC 2010;56:2182-99
   Google Scholar
• Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47
   PubMed Web of Science ®Google Scholar
• Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-9
   PubMed Web of Science ®Google Scholar
• Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008;118:2243-51
   PubMed Web of Science ®Google Scholar
• Olsen MH, Hansen TW, Christensen MK, et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 2007;28:1374-81
   PubMed Web of Science ®Google Scholar
• Eaton CB, Galliher JM, McBride PE, et al. Family physician’s knowledge, beliefs, and self-reported practice patterns regarding hyperlipidemia: a National Research Network (NRN) survey. J Am Board Fam Med 2006;19:46-53
   PubMed Web of Science ®Google Scholar
• Montgomery AA, Fahey T, MacKintosh C, et al. Estimation of cardiovascular risk in hypertensive patients in primary care. Br J Gen Pract 2000;50:127-8
   PubMed Web of Science ®Google Scholar
• Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43
   PubMed Web of Science ®Google Scholar
• Zethelius B, Berglund L, Sundstrom J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008;358:2107-16
   PubMed Web of Science ®Google Scholar
• Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012;308:788-95
   PubMed Web of Science ®Google Scholar
• Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119:2408-16
   PubMed Web of Science ®Google Scholar
• Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J 2009;157:111-17 e2
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Zeller T, Saarela O, et al. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 2010;121:2388-97
   PubMed Web of Science ®Google Scholar
• Kavousi M, Elias-Smale S, Rutten JHW, et al. Evaluation of newer risk markers for coronary heart disease risk classification. Ann Intern Med 2012;156:438-44
   PubMed Web of Science ®Google Scholar
• Hill S, Spink J, Cadilhac D, et al. Absolute risk representation in cardiovascular disease prevention: comprehension and preferences of health care consumers and general practitioners involved in a focus group study. BMC Public Health 2010;10:108
   PubMed Web of Science ®Google Scholar
• Tabibiazar R, Wagner RA, Ashley EA, et al. Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary disease. Physiol Genomics 2005;22:213-26
   PubMed Web of Science ®Google Scholar
• Ardigo D, Assimes TL, Fortmann SP, et al. Circulating chemokines accurately identify individuals with clinically significant atherosclerotic heart disease. Physiol Genomics 2007;31:402-9
   PubMed Web of Science ®Google Scholar
• McCarty CA, Wilke RA, Giampietro PF, et al. Marshfield Clinic Personalized Medicine Research Project (PMRP): design, methods and recruitment for a large population-based biobank. Personalized Med 2005;2:49-79
   PubMedGoogle Scholar
• Bild DE. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol 2002;156:871-81
   PubMed Web of Science ®Google Scholar
• Cai J, Zeng D. Power calculation for case-cohort studies with nonrare events. Biometrics 2007;63:1288-95
   PubMed Web of Science ®Google Scholar
• R Development Core Team. R: A Language and Environment for Statistical Computing (Linux v2.9.0 and Windows v2.12.2), 2011 edn. Vienna, Austria: R Foundation for Statistical Computing, 2011
   Google Scholar
• Cox DR. Regression models and life-tables. J Royal Stat Soc Series B 1972;34:187-220
   Web of Science ®Google Scholar
• NCEP Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• Hastie T, Tibshirani R, Friedman J. The Elements of Statistical Learning: Data Mining, Inference and Prediction, 2nd edn. New York, NY: Springer, 2009
   Google Scholar
• Tibshirani RJ, Efron B. Pre-validation and inference in microarrays. Stat Appl Genet Mol Biol 2002;1:Article1
   PubMedGoogle Scholar
• Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 2008;54:17-23
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21
   PubMed Web of Science ®Google Scholar
• Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004;23:2109-23
   PubMed Web of Science ®Google Scholar
• Auer R, Bauer DC, Marques-Vidal P, et al. Association of major and minor ECG abnormalities with coronary heart disease events. JAMA 2012;307:1497-505
   PubMed Web of Science ®Google Scholar
• Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000;19:453-73
   PubMed Web of Science ®Google Scholar
• Tabibiazar R, Wagner RA, Deng A, et al. Proteomic profiles of serum inflammatory markers accurately predict atherosclerosis in mice. Physiol Genomics 2006;25:194-202
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Martin-Ventura JL, de Teresa E, et al. Increased soluble Fas plasma levels in subjects at high cardiovascular risk. Arterioscler Thromb Vasc Biol 2007;27:168-74
   PubMed Web of Science ®Google Scholar
• Mateo T, Naim Abu Nabah Y, Abu Taha M, et al. Angiotensin II-induced mononuclear leukocyte interactions with arteriolar and venular endothelium are mediated by the release of different CC chemokines. J Immunol 2006;176:5577-86
   PubMed Web of Science ®Google Scholar
• Castillo L, Rohatgi A, Ayers CR, et al. Associations of four circulating chemokines with multiple atherosclerosis phenotypes in a large population-based sample. J Interferon Cytokine Res 2010;30:339-47
   PubMed Web of Science ®Google Scholar
• Struthers A, Lang C. The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage. Eur Heart J 2007;28:1678-82
   PubMed Web of Science ®Google Scholar
• Reiter M, Twerenbold R, Reichlin T, et al. Early diagnosis of acute myocardial infarction in patients with pre-existing coronary artery disease using more sensitive cardiac troponin assays. Eur Heart J 2012;33:988-97
   PubMed Web of Science ®Google Scholar
• Saunders JT, Nambi V, de Lemos JA, et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 2011;123:1367-76
   PubMed Web of Science ®Google Scholar
• Whittemore AS. Evaluating health risk models. Stat Med 2010;29:2438-52
   PubMed Web of Science ®Google Scholar
• Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115:928-35
   PubMed Web of Science ®Google Scholar
• Janes H, Pepe MS, Gu W. Assessing the value of risk predictions by using risk stratification tables. Ann Intern Med 2008;149:751-60
   PubMed Web of Science ®Google Scholar
• Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 2009;302:49-57
   PubMed Web of Science ®Google Scholar
• Lim LS, Haq N, Mahmood S, et al. Atherosclerotic cardiovascular disease screening in adults: American College of Preventive Medicine position statement on preventive practice. Am J Prev Med 2011;40:381.e1-10
   Web of Science ®Google Scholar
• Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003;290:898-904
   PubMed Web of Science ®Google Scholar
• Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update. Circulation 2011;123:1243-62
   PubMed Web of Science ®Google Scholar
• Farley TA, Dalal MA, Mostashari F, et al. Deaths preventable in the U.S. by improvements in use of clinical preventive services. Am J Prev Med 2010;38:600-9
   PubMed Web of Science ®Google Scholar
• Lardizabal JA, Deedwania PC. Benefits of statin therapy and compliance in high risk cardiovascular patients. Vasc Health Risk Manag 2010;6:843-53
   PubMedGoogle Scholar
• Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care 2006;12:21-8
   PubMed Web of Science ®Google Scholar
• Nolan N, Tee L, Vijayakumar S et al. Analytical validation of a coronary heart disease risk assessment multi-analyte proteomic test. Submitted 2012
   Google Scholar